Modern approaches to risk stratification and prognosis assessment in patients with pulmonary arterial hypertension
https://doi.org/10.38109/2075-082X-2026-1-9-16
Abstract
Pulmonary arterial hypertension is a severe progressive disease with a high mortality risk, requiring an accurate prognosis assessment to optimize therapy. Risk stratification plays a key role in predicting survival and choosing treatment tactics. Modern approaches in risk stratification are based on an integrated assessment of clinical, hemodynamic, laboratory and instrumental parameters to identify patients with low, intermediate and high risk of death within 1 year, which allows to personalize treatment: from monotherapy to aggressive combination regimens and referral for transplantation.
Keywords
pulmonary arterial hypertension,
risk stratification,
prognostic parameters,
national and international registries,
pulmonary arterial hypertension risk stratification tools.
Supporting agencies: no
About the Authors
Elena A. Karazei
Belarusian State Medical University
Belarus
Belarus
Elena A. Karazei, Cand. Of Scien. (Med.), Associate Professor, Department of Outpatient Therapy,
83/Bldg. 1, Dzerzhinsky Ave., Minsk 220083.
Igor E. Adzerikho
Belarusian State Medical University
Belarus
Belarus
Igor E. Adzerikho, Dr. Of Scien. (Med.), AProfessor, Department of Clinical Pharmacology and Pharmacotherapy, Institute for Advanced Training and Retraining of Healthcare Personnel,
83/Bldg. 1, Dzerzhinsky Ave., Minsk 220083.
Alina A. Кoroliova
Belarusian State Medical University
Belarus
Belarus
Alina A. Кoroliova, Cand. Of Scien. (Med.), Associate Professor, Department of Clinical Pharmacology,
83/Bldg. 1, Dzerzhinsky Ave., Minsk 220083.
Ludmila V. Karanevich
Healthcare Institution "6th Central District Clinical Polyclinic of the Leninsky District of Minsk"
Belarus
Belarus
Lyudmila V. Karanevich, Physician, Medical Rehabilitation Department,
5, Ulyanovskaya St., Minsk, 220030.
References
1. Chazova I.E., Martynyuk T.V., Valieva Z.S., et al. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension. Eurasian heart journal. 2020;(1):78-122. (In Russ.) https://doi.org/10.38109/2225-1685-2020-1-78-122
2. Humbert М, Kovacs G, Hoeper M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43:3618-3731. https://doi.org/10.1183/13993003.00879-2022
3. The Seventh World Symposium on Pulmonary Hypertension: a collection of articles comprising the Proceedings of the Seventh World Symposium on Pulmonary Hypertension. European Respiratory Journal. 2024;URL https://publications.ersnet.org/content/erj (date of access: 23.06.2025).
4. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Annals of Internal Medicine. 1987;107(2):216-223. https://doi.org/10.7326/0003-4819-107-2-216
5. Shariya AM, Martynyuk TV. Data of modern registries on clinical course and prognosis of patients with idiopathic pulmonary arterial hypertension. Russian Cardiology Bulletin. 2021;16(3):23 27. (In Russ.) https://doi.org/10.17116/Cardiobulletin20211603123
6. Humbert M, Sitbon O, Yaïci A, et al. French pulmonary arterial hypertension network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. European Respiratory Journal. 2010;36(3):549-555. https://doi.org/10.1183/09031936.00057010
7. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012;142(2):448-456. https://doi.org/10.1378/chest.11-1460
8. Rådegran G, Kjellström B, Ekmehag B, et al. Characteristics and survival of adult Swedish PAH and CTEPH patients 2000-2014. Scand Cardiovasc J.2016;50(4):243-250. https://doi.org/10.1080/14017431.2016.1185532
9. Hoeper MM, Pausch C, Grünig E, et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. The Journal of Heart and Lung Transplantation. 2020;39(12):1435-1444. https://doi.org/10.1016/j.healun.2020.09.011
10. Avdeev S.N., Barbarash O.L., Valieva Z.S., et al. 2024 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2024;29(11): 170-250. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6161
11. Barst RJ, Chung L, Zamanian RT, et al. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest. 2013;144(1):160-168. https://doi.org/10.1378/chest.12-2417
12. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012;60(13):1192–1201.
13. Pulmonary hypertension/ edited by I.E. Chazova, T.V. Martynyuk. – M: Praktika, 2015. – 928 p. (In Russ.) ISBN 978-5-89816-138-5]
14. Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J. 2018;32:503-512. https://doi.org/10.1183/09031936.00160307
15. Tello K, Axmann J, Ghofrani HA, et al. Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. Int J Cardiol. 2018;266:229-235. https://doi.org/10.1016/j.ijcard.2018.01.053
16. van der Bruggen CE, Handoko ML, Bogaard HJ, et al. The Value of Hemodynamic Measurements or Cardiac MRI in the Follow-up of Patients With Idiopathic Pulmonary Arterial Hypertension. Chest. 2021 Apr;159(4):1575-1585. https://doi.org/10.1016/j.chest.2020.10.077
17. Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175-4181. https://doi.org/10.1093/eurheartj/ehx257
18. Benza RL, Kanwar MK, Raina A, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. Chest. 2021;159(1):337-346. https://doi.org/10.1016/j.chest.2020.08.2069
19. PAH Risk Score Calculators: [site]. – [United Therapeutics Corporation], 2024. – URL: https://www.pahinitiative.com/hcp/risk-assessment/calculators (date of access: 30.08.2024).
20. Benza RL, Gomberg Maitland MI, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323-337. https://doi.org/10.1016/j.chest.2019.02.004
21. Raina A, Humbert M. Risk assessment in pulmonary arterial hypertension. Eur Respir Rev.2016;25(142):390-398. https://doi.org/10.1183/16000617.0077-2016
22. Simons J.E. Mann D, Pierozynski A. Assessment of risk of disease progression in pulmonary arterial hypertension: insights from an international survey of clinical practice. Adv Ther. 2019;36(9):2351-2363. https://doi.org/10.1007/s12325-019-01030-4
23. Boucly A, Weatherald J, Humbert M, Sitbon O. Risk assessment in pulmonary arterial hypertension. Eur Respir J. 2018;51(3):1800279. https://doi.org/10.1183/13993003.00279-2018
24. Hoeper MM, Pausch C, Olsson KM, et al. COMPERA 2.0: a refined 4-strata risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60(1): 2102311. https://doi.org/10.1183/13993003.02311-2021
25. Boucly A, Weatherald J, Savale L, et al. External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension registry. Eur Respir J. 2022;59(6):2102419. https://doi.org/10.1183/13993003.02419-2021
Review
For citations:
Karazei E.A., Adzerikho I.E., Кoroliova A.A., Karanevich L.V. Modern approaches to risk stratification and prognosis assessment in patients with pulmonary arterial hypertension. Systemic Hypertension. 2026;23(1):9-16. (In Russ.) https://doi.org/10.38109/2075-082X-2026-1-9-16
Views:
256
JATS XML
Email this article 